Aditxt, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Aditxt, Inc. (ADTX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$32.70 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-16.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-04-16
- Aditxt, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$11.12M.
- Aditxt, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-09-30 was -$9.91M.
- Aditxt, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-06-30 was -$5.68M.
- Aditxt, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-03-31 was -$5.98M.
- Aditxt, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$32.70M.
- Aditxt, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$27.69M.
- Aditxt, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$46.27M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | -$11.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$21.03M derived: sum of 2 quarters · filed 2024-04-16 | -$26.72M derived: sum of 3 quarters · filed 2024-04-16 | -$32.70M 10-K · filed 2024-04-16 | |||
| 2023-09-30 | -$9.91M 10-Q · filed 2023-11-14 | -$15.60M derived: sum of 2 quarters · filed 2024-04-16 | -$21.58M 10-Q · filed 2023-11-14 | -$29.80M derived: sum of 4 quarters · filed 2024-04-16 | |||
| 2023-06-30 | -$5.68M derived: 10-K 12 month − 3 quarters · filed 2024-04-16 | -$11.67M derived: sum of 2 quarters · filed 2024-04-16 | -$19.89M derived: sum of 3 quarters · filed 2024-04-16 | -$27.45M derived: sum of 4 quarters · filed 2024-04-16 | |||
| 2023-03-31 | -$5.98M 10-Q · filed 2023-05-15 | -$14.21M derived: sum of 2 quarters · filed 2024-04-16 | -$21.76M derived: sum of 3 quarters · filed 2024-04-16 | -$23.56M derived: sum of 4 quarters · filed 2024-04-16 | |||
| 2022-12-31 | -$8.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$15.78M derived: sum of 2 quarters · filed 2024-04-16 | -$17.57M derived: sum of 3 quarters · filed 2024-04-16 | -$27.69M 10-K · filed 2024-04-16 | -$27.61M 10-K · filed 2023-04-17 | ||
| 2022-09-30 | -$7.56M 10-Q · filed 2023-11-14 | -$9.35M derived: sum of 2 quarters · filed 2023-11-14 | -$19.47M 10-Q · filed 2023-11-14 | -$15.67M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$7.85M 10-Q · filed 2022-08-15 | |||||
| 2022-03-31 | -$6.06M 10-Q · filed 2023-05-15 | -$5.20M 10-Q · filed 2022-05-16 | |||||
| 2021-12-31 | -$46.27M 10-K · filed 2023-04-17 | -$22.28M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |